RET and lung adenocarcinoma: RET fusion-positive lung adenocarcinoma occurs in 1%–2% of cases, and clinical trials of multikinase inhibitors that inhibit RET oncogene activity such as vandetanib and cabozantinib have indicated their antitumor efficacy.